Evidence map›Paper›PMID 31140202›Full record

Trial reportPsycho-oncology2019

The effects of weight loss and metformin on cognition among breast cancer survivors: Evidence from the Reach for Health study.

Sheri J Hartman, Sandahl H Nelson, Catherine R Marinac, Loki Natarajan, Barbara A Parker, Ruth E Patterson

Open access · bronzeAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Psycho-oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 2 pooled it
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Sheri J HartmanDepartment of Family Medicine and Public Health, UC San Diego, La Jolla, California.ORCID 0000-0002-3719-0624
Sandahl H NelsonDepartment of Family Medicine and Public Health, UC San Diego, La Jolla, California.
Catherine R MarinacDivision of Population Sciences, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0002-9128-3012
Loki NatarajanDepartment of Family Medicine and Public Health, UC San Diego, La Jolla, California.ORCID 0000-0001-5719-828X
Barbara A ParkerUC San Diego Moores Cancer Center, UC San Diego, La Jolla, California.
Ruth E PattersonDepartment of Family Medicine and Public Health, UC San Diego, La Jolla, California.
UC San Diego Health System · USHarvard University · US

Funding

UCSD Biorepository Shared ResourceU54CA155435 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI PATTERSON, RUTH E · 2011 to 2015
$9.1M
Physical Activity and neuropsychological outcomes in a cancer populationK07CA181323 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI HARTMAN, SHERI J · 2014 to 2018
$852k
Obesity, Molecular Biomarkers, and Multiple Myeloma PrognosisF32CA220859 · NCI · DANA-FARBER CANCER INST · PI MARINAC, CATHERINE · 2018 to 2019
$94k
NCI NIH HHS F32 CA220859NCI NIH HHS F32CA220859NCI NIH HHS K07 CA181323NCI NIH HHS K07CA181323NCI NIH HHS U54 CA155435
6 · The paper itself

Abstract

objectiveBreast cancer survivors experience problems with cognition that interfere with daily life and can last for years. In the general population, obesity and diabetes are risk factors for cognitive decline, and weight loss can improve cognition; however, the impact of intentional weight loss on cancer survivors' cognition has not been tested. We investigated the impact of weight loss and metformin on changes in cognitive function in a sample of breast cancer survivors.

methodsOverweight/obese postmenopausal breast cancer survivors (n = 333) were randomized to a weight loss intervention versus control and metformin versus placebo in a 2 × 2 factorial design. Outcomes were changes in five cognitive domains from baseline to 6 months measured by objective neurocognitive tests.

resultsThere were no statistically significant intervention effects for the metformin or weight loss interventions in five neurocognitive domains. Baseline body mass index (BMI) was a significant effect modifier of the changes in verbal functioning for the weight loss (P = 0.009) and metformin interventions (P = 0.0125). These effect modifications were independent of percent weight loss achieved during the 6-month study period.

conclusionsThis randomized controlled trial of weight loss and metformin interventions that examined changes to cognition among breast cancer survivors suggests that these interventions may not improve cognitive functioning among breast cancer survivors in general. However, weight loss may improve verbal functioning among individuals with a higher BMI.

Indexed as

Breast NeoplasmsCancer SurvivorsWeight LossAgedAged, 80 and overCognitive DysfunctionCombined Modality TherapyFemaleHumansHypoglycemic AgentsMetforminMiddle AgedObesityOutcome Assessment, Health CareOverweightHypoglycemic AgentsMetformincancer survivorscognitionmetforminobesityweight loss

Identifiers

PMID31140202
PMCPMC6791123
OpenAlexW2946889513

What OpenQuestion holds

Texttitle and abstract
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.